Sylvie Perreault

Prof. Sylvie Perreault


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2005 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
SPSylvie Perreault
Sylvie Perreault
LBL. Blais
L. Blais
DLD. Lamarre
D. Lamarre
ADA. Dragomir
A. Dragomir
DBD. Berbiche
D. Berbiche
JCJ. Collin
J. Collin
Aims: Statins have been shown to significantly reduce morbidity and mortality in patients with coronary artery disease (CAD), and also in patients with dyslipidaemia when statins are taken regularly. Middle‐aged patients have the highest level of forecasting benefit and little is known about persistence rate of these therapies in a real‐life setting. The objective was to evaluate the persistence rate of middle‐aged patients initiating a statin therapy and its relation with several determinants for primary and secondary prevention.Methods: A cohort was reconstructed using the RAMQ databases. All patients aged 50–64 years‐old who received at least one statin prescription between 1 January, 1998 and 31 December, 2000 for a new intention of treatment for dyslipidaemia were included in the cohort and followed up until 30 June, 2001. The date of the first prescription of statin was defined as the index date. There were 4316 patients in the secondary prevention (CAD diagnosis) and 13 642 patients in primary prevention cohort. The cumulative persistence rate was estimated using Kaplan‐Meier, and Cox regression models were used to estimate the hazard ratio of ceasing statins.Results: We found that persistence with statins had fallen to 71% after 6 months of treatment, and had declined to 45% after 3 years in the secondary prevention cohort; the corresponding figures were 65% and 35% in the primary prevention cohort. Our results suggest that patients with dyslipidaemia in primary prevention compared with those in secondary prevention (HR: 1.18; 1.11–1.25) are less likely to be persistent. Patients with other cardiovascular risk factors such as age (HR: 0.99; 0.98–0.99), diabetes (HR: 0.84; 0.79–0.90), hypertension (HR: 0.76; 0.72–0.80) were most likely to be persistent with statins. We observed lower persistence in patients who have used the greatest number of pharmacies and prescribing physicians.Conclusion: This analysis indicates that barriers to persistence occur early in the therapeutic course. Overall persistence with statins is low, and particularly among patients with few other cardiovascular risk factors.

19 September 2023 in Circulation
Verified
Journal Article
Closed access
RARahul Aggarwal
Rahul Aggarwal
CRChristian T. Ruff
Christian T. Ruff
SVSaverio Virdone
Saverio Virdone
SPSylvie Perreault
Sylvie Perreault
AKAjay K. Kakkar
Ajay K. Kakkar
RYRobert W. Yeh
Robert W. Yeh
BACKGROUND: Current clinical decision tools for assessing bleeding risk in individuals with atrial fibrillation (AF) have limited performance and were developed for individuals treated with warfarin. This study develops and validates a clinical risk score to personalize estimates of bleeding risk for individuals with atrial fibrillation taking direct-acting oral anticoagulants (DOACs). METHODS: Among individuals taking dabigatran 150 mg twice per day from 44 countries and 951 centers in this secondary analysis of the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), a risk score was developed to determine the comparative risk for bleeding on the basis of covariates derived in a Cox proportional hazards model. The risk prediction model was internally validated with bootstrapping. The model was then further developed in the GARFIELD-AF registry (Global Anticoagulant Registry in the Field-Atrial Fibrillation), with individuals taking dabigatran, edoxaban, rivaroxaban, and apixaban. To determine generalizability in external cohorts and among individuals on different DOACs, the risk prediction model was validated in the COMBINE-AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) pooled clinical trial cohort and the Quebec Régie de l’Assurance Maladie du Québec and Med-Echo Administrative Databases (RAMQ) administrative database. The primary outcome was major bleeding. The risk score, termed the DOAC Score, was compared with the HAS-BLED score. RESULTS: Of the 5684 patients in RE-LY, 386 (6.8%) experienced a major bleeding event, within a median follow-up of 1.74 years. The prediction model had an optimism-corrected C statistic of 0.73 after internal validation with bootstrapping and was well-calibrated based on visual inspection of calibration plots (goodness-of-fit P =0.57). The DOAC Score assigned points for age, creatinine clearance/glomerular filtration rate, underweight status, stroke/transient ischemic attack/embolism history, diabetes, hypertension, antiplatelet use, nonsteroidal anti-inflammatory use, liver disease, and bleeding history, with each additional point scored associated with a 48.7% (95% CI, 38.9%–59.3%; P <0.001) increase in major bleeding in RE-LY. The score had superior performance to the HAS-BLED score in RE-LY (C statistic, 0.73 versus 0.60; P for difference <0.001) and among 12 296 individuals in GARFIELD-AF (C statistic, 0.71 versus 0.66; P for difference = 0.025). The DOAC Score had stronger predictive performance than the HAS-BLED score in both validation cohorts, including 25 586 individuals in COMBINE-AF (C statistic, 0.67 versus 0.63; P for difference <0.001) and 11 945 individuals in RAMQ (C statistic, 0.65 versus 0.58; P for difference <0.001). CONCLUSIONS: In individuals with atrial fibrillation potentially eligible for DOAC therapy, the DOAC Score can help stratify patients on the basis of expected bleeding risk.

22 November 2019 in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Verified
Journal Article
Closed access
PDF file
SPSylvie Perreault
Sylvie Perreault
SDSimon de Denus
Simon de Denus
BWBrian White‐Guay
Brian White‐Guay
RCRobert Côté
Robert Côté
MSMireille E. Schnitzer
Mireille E. Schnitzer
Jean-Claude TardifJean-Claude Tardif
Jean-Claude Tardif

15 March 2012 in BMC Public Health
Verified
Journal Article
Open access
PDF file
MLMarie-Claude Laliberté
Marie-Claude Laliberté
SPSylvie Perreault
Sylvie Perreault
NDNicole Damestoy
Nicole Damestoy
LLLyne Lalonde
Lyne Lalonde
Background: An increased interest is observed in broadening community pharmacists' role in public health. To date, little information has been gathered in Canada on community pharmacists' perceptions of their role in health promotion and prevention; however, such data are essential to the development of public-health programs in community pharmacy. A cross-sectional study was therefore conducted to explore the perceptions of community pharmacists in urban and semi-urban areas regarding their ideal and actual levels of involvement in providing health-promotion and prevention services and the barriers to such involvement.Methods: Using a five-step modified Dillman's tailored design method, a questionnaire with 28 multiple-choice or open-ended questions (11 pages plus a cover letter) was mailed to a random sample of 1,250 pharmacists out of 1,887 community pharmacists practicing in Montreal (Quebec, Canada) and surrounding areas. It included questions on pharmacists' ideal level of involvement in providing health-promotion and preventive services; which services were actually offered in their pharmacy, the employees involved, the frequency, and duration of the services; the barriers to the provision of these services in community pharmacy; their opinion regarding the most appropriate health professionals to provide them; and the characteristics of pharmacists, pharmacies and their clientele.Results: In all, 571 out of 1,234 (46.3%) eligible community pharmacists completed and returned the questionnaire. Most believed they should be very involved in health promotion and prevention, particularly in smoking cessation (84.3%); screening for hypertension (81.8%), diabetes (76.0%) and dyslipidemia (56.9%); and sexual health (61.7% to 89.1%); however, fewer respondents reported actually being very involved in providing such services (5.7% [lifestyle, including smoking cessation], 44.5%, 34.8%, 6.5% and 19.3%, respectively). The main barriers to the provision of these services in current practice were lack of: time (86.1%), coordination with other health care professionals (61.1%), staff or resources (57.2%), financial compensation (50.8%), and clinical tools (45.5%).Conclusions: Although community pharmacists think they should play a significant role in health promotion and prevention, they recognize a wide gap between their ideal and actual levels of involvement. The efficient integration of primary-care pharmacists and pharmacies into public health cannot be envisioned without addressing important organizational barriers.

3 January 2007 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
MBMarie‐Hélène Bouchard
Marie‐Hélène Bouchard
ADAlice Dragomir
Alice Dragomir
LBLucie Blais
Lucie Blais
ABAnick Bérard
Anick Bérard
DPDanielle Pilon
Danielle Pilon
SPSylvie Perreault
Sylvie Perreault
What is already known about this subject • There is a major gap between the use of statins in clinical trial settings and in actual practice.• Unfortunately, little is known about the impact of suboptimal use of statins on clinical outcomes. What this study adds • Patients who filled more than 90% of the prescribed doses began to achieve significant reductions in nonfatal coronary artery disease events.• Statin effectiveness is apparent after one full year of treatment.Aims: To evaluate the impact of adherence to statins on nonfatal coronary artery disease (CAD). Statins reduce cardiovascular morbidity and mortality after 1–2 years of continuous treatment. Studies have shown that <40% of patients take ≥80% of prescribed doses 1 year after starting therapy and that approximately half discontinue medication within 6 months of starting therapy.Methods: A cohort of 20 543 patients was reconstructed using the Régie de l'assurance maladie du Québec databases. Patients aged 50–64 years, without cardiovascular disease, and newly treated with statins between 1998 and 2000 were eligible. A nested case–control design was used to study nonfatal CAD. Every case was matched with 20 randomly selected controls. The adherence level was defined as the percentage of the prescribed medication doses used over a specified period and classified as ≥90% or 1 year, adherence of ≥90% was associated with fewer nonfatal CAD events (RR 0.81; 0.67, 0.97) compared with adherence 90% of the prescribed medications is used over at least 1 year.

16 June 2009 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SPSylvie Perreault
Sylvie Perreault
ADAlice Dragomir
Alice Dragomir
LBLucie Blais
Lucie Blais
ABAnick Bérard
Anick Bérard
LLLyne Lalonde
Lyne Lalonde
DPDanielle Pilon
Danielle Pilon